Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Studies Commence to Ensure Reliability of HIV 1/2 Assay

By LabMedica International staff writers
Posted on 02 May 2013
An HIV 1/2 assay detects antibodies to HIV 1 and 2 in oral fluid, finger-stick whole blood (fingerstick), venous whole blood, serum, or plasma samples. More...


Chembio Diagnostics' (Medford, NY, USA) DPP HIV 1/2 assay provides a simple "reactive/nonreactive" result. In a clinical evaluation of over 3,000 patients across three countries, the diagnostic sensitivity of the DPP HIV 1/2 assay to detect HIV infection ranged from 99.9%–100% for fingerstick specimens and 98.9%–100% for oral fluid specimens. The diagnostic specificity of the DPP HIV 1/2 assay was 100% for fingerstick specimens and 99.9%–100% for oral fluid specimens. The test is intended to be used in the preliminary diagnosis of patients with HIV in point-of-care (POC) settings such as public health and other clinics, hospital emergency rooms and physician offices.

The assay does not use lateral flow or other older flow-through technologies. DPP HIV 1/2 delivers visual results within approximately 15 minutes, is simple to use, requires minimal sample size, has a shelf life of 24 months, and does not require refrigeration. Providing results at the POC eliminates the chance that patients at risk would not return or call back for results, thereby improving prevention efforts of forward transmission.

A convenient swab for collection of oral fluid samples is a feature of DPP HIV 1/2. Sharp distinct test lines are obtained due to the DPP technology. The sample collection system enables each sample to be contained in a convenient, closed collection vial, or Sampletainer, which provides additional sample for repeat testing.

Although the US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved Chembio's new DPP HIV 1/2 Assay multisite assay in December 2012, it requires Clinical Laboratory Improvement Amendments (CLIA) waiver studies to establish the quality standards for laboratory testing. These must ensure the accuracy, reliability, and timeliness of patient tests results regardless of where the tests are performed.

The CLIA clinical study will test samples prospectively collected from approximately 1,000 subjects who are HIV positive and of unknown HIV status. The study is expected to be completed within three to four months. The company anticipates that the FDA's review of the CLIA Waiver Application will be completed during the fourth quarter of 2013.

"We are very pleased to commence the CLIA clinical testing for our DPP HIV 1/2 Assay. It is a key component for Chembio as we finalize our commercial strategy to launch the DPP assay in the US," noted Lawrence Siebert, Chembio's CEO.

Related Links:
Chembio Diagnostics




New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Pancreas cells (left) showing early stages of malignant cancer in brown and same cells stained blue (right) indicate they are Integrin β3 (ITGB3) positive (Photo courtesy of UC San Diego Health Sciences)

Gene Signature Could Serve as Early Warning System for Aggressive Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer, with early detection remaining a major challenge. Precancerous cells must overcome significant stress and... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.